{"id":"W3020482066","doi":"10.1016/s1470-2045(20)30112-1","title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":261,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Eisai; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Fulvestrant; Internal medicine; Breast cancer; Oncology; Metastatic breast cancer; Cancer; Chemotherapy; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001307475,0.002001432,0.002575106,0.0005000026,0.0002959456,0.001105097,0.001024521,0.00163503,0.009329692],"category_scores_gemma":[0.001623816,0.0006671583,0.001852372,0.000391959,0.001159372,0.001326589,0.0005296693,0.003188795,0.001422903],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009588978,"about_ca_system_score_gemma":0.0008701767,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001270915,"about_ca_topic_score_gemma":0.003658818,"domain_scores_codex":[0.9995666,0.0002145926,0.00001914741,0.00008394379,0.00003043216,0.00008529547],"domain_scores_gemma":[0.9994572,0.0001721681,0.0001061856,0.00004734139,0.00002858322,0.0001885411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9797411,0.003917407,0.0002775886,0.0004910358,0.0006479237,0.00002618688,0.00004396004,0.0003440326,0.001598271,0.0001383713,0.0007936193,0.01198049],"study_design_scores_gemma":[0.9608486,0.03676104,0.0008255835,0.0000253073,0.0002997323,0.00002519664,0.00002155431,0.0002713848,0.0001804688,0.0001831144,0.0005461358,0.00001175772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844931,0.005674563,0.0005107163,0.00122794,0.0009813972,0.002129334,0.001332192,0.0001567001,0.003494104],"genre_scores_gemma":[0.9799712,0.004053375,0.001270855,0.001419607,0.0006643896,0.002402688,0.001666187,0.00004346464,0.008508307],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009329692,"threshold_uncertainty_score":0.03121096,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05342743091466359,"score_gpt":0.3829554564653619,"score_spread":0.3295280255506983,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}